Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on Immunotherapy for TNBC: IMpassion130 Results
Posted: Thursday, October 25, 2018
Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, and Lisa A. Carey, MD, of the University of North Carolina, discuss the phase III IMpassion 130 trial testing the first-line combination of the PD-L1 inhibitor atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
